RESEARCHER PROFILE

Yu Jung Kim

Gachon University

Lung Cancer Treatments and MutationsPalliative Care and End-of-Life IssuesCancer Immunotherapy and BiomarkersPalliative and Oncologic CareLung Cancer Diagnosis and Treatment

Yu Jung Kim works in Lung Cancer Treatments and Mutations, Palliative Care and End-of-Life Issues, Cancer Immunotherapy and Biomarkers, Palliative and Oncologic Care, Lung Cancer Diagnosis and Treatment. Recorded institutional associations include Gachon University, Seoul National University, Seoul National University Bundang Hospital.

422Publications

9,321Citations

47H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

← Return to the university profile

Yu Jung Kim

Gachon University

Selected research works

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

High EGFR gene copy number predicts poor outcome in triple-negative breast cancer

Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer

Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

Integration of Oncology and Palliative Care: A Systematic Review

Avoidable and Unavoidable Visits to the Emergency Department Among Patients With Advanced Cancer Receiving Outpatient Palliative Care

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody

REL1, a Homologue of Drosophila Dorsal, Regulates Toll Antifungal Immune Pathway in the Female Mosquito Aedes aegypti

Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering

Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity

Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme

Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea

The role of NF-κB factor REL2 in the Aedes aegypti immune response

The role of PET/CT in detection of gastric cancer recurrence

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors